FIREFISH 2-year data show continued benefit of risdiplam for type 1 SMA
The 24-month results from part 2 of the open-label FIREFISH trial suggest that prolonged treatment with risdiplam is associated with continued improvements in motor function and development in infants with type 1 spinal muscular atrophy.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Research identifies sex differences in SSc-ILD outcomes
Men with systemic sclerosis-associated interstitial lung disease may have a more severe disease course than women, whereas women with the condition could be more likely to experience certain adverse events when treated with immunosuppressive therapy, suggest findings from two studies.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Meta-analysis backs SGLT2 inhibitors for kidney disease
A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.
Real-world adjunctive medication outcomes in type 1 diabetes revealed
People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.
VALOR hints at potential benefit of tofersen for SOD1 amyotrophic lateral sclerosis
Data from the open-label extension of the VALOR trial suggest that treatment with the intrathecally administered antisense oligonucleotide tofersen may modify the disease course of amyotrophic lateral sclerosis due to SOD1 mutations and lead to improvements in function.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Minimal access breast surgery ‘valid’ option for early breast cancer
Minimal access breast surgery offers comparable long-term outcomes to conventional surgery for women with stage 0–III breast cancer, show the results of a propensity-matched, retrospective cohort study.
Prophylactic antivirals may help prevent symptomatic COVID-19 in rituximab-treated patients
Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.
Diabetes ‘no longer a CVD risk equivalent’
The strength of the association between diabetes and the risk for cardiovascular events has lessened over recent years, report researchers.
Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors
The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology.
Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease
JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.